Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOWNB4)

Drug Name
2,3-dihydroxypropanal Drug Info
Synonyms
DL-Glyceraldehyde; glyceraldehyde; 2,3-Dihydroxypropanal; Glyceric aldehyde; Glycerose; Glycerinaldehyde; Glycerinformal; 56-82-6; Propanal, 2,3-dihydroxy-; 2,3-Dihydroxypropionaldehyde; DL-GLYC; Aldotriose; alpha,beta-dihydroxypropionaldehyde; 367-47-5; Glyceraldehyde, (+-)-; Propionaldehyde, 2,3-dihydroxy-; aldose; U 1188; D,L-glyceraldehyde; NSC 67934; BRN 0635844; AI3-24475; (+/-)-Glyceraldehyde; EINECS 206-695-9; EINECS 200-290-0; DLG; .alpha.,.beta.-Dihydroxypropionaldehyde; 2,3-dihydroxy-propionaldehyde; CHEBI:5445
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
751
ChEBI ID
CHEBI:5445
CAS Number
CAS 56-82-6
TTD Drug ID
DMOWNB4
INTEDE Drug ID
DR1997

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Aldose reductase (AKR1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epalrestat DM5OGK0 Diabetic neuropathy 8C0Z Approved [7]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [8]
Fidarestat DMZL1I8 Diabetic complication 5A2Y Phase 3 [9]
Ranirestat DMD5QRS Diabetic neuropathy 8C0Z Phase 3 [10]
CONTIGOSIDE B DMX9V8K Thrombosis DB61-GB90 Phase 2/3 [11]
BNV-222 DMYFQJL Diabetic neuropathy 8C0Z Phase 2/3 [10]
BNV-222 DMYFQJL Diabetic neuropathy 8C0Z Phase 2/3 [12]
LIDORESTAT DMA0RI9 Diabetic complication 5A2Y Phase 2 [13]
QR-333 DMKVIWM Diabetic neuropathy 8C0Z Phase 2 [14]
ADMVA DM819CO Diabetic complication 5A2Y Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Aldo-keto reductase 1A1 (AKR1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [15]
Ethanol DMDRQZU Chronic pain MG30 Approved [16]
NADH DM5NM6E Parkinson disease 8A00.0 Approved [17]
Nitrobenzaldehyde DM4UHB5 N. A. N. A. Investigative [2]
D-glucuronate DM1YBTC N. A. N. A. Investigative [2]
BRN-0471734 DMZMWVX N. A. N. A. Investigative [2]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member B10 (AKR1B10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [18]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [19]
Quercetin DM3NC4M Obesity 5B81 Approved [20]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [21]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [22]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [23]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [24]
Reserpine DM6VM38 Hypertension BA00-BA04 Approved [25]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [26]
Disulfiram DMCL2OK Alcohol dependence 6C40.2 Approved [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member B1 (AKR1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [20]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [28]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [29]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [30]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [31]
Disulfiram DMCL2OK Alcohol dependence 6C40.2 Approved [27]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [32]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [33]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [34]
Benzoic Acid DMKB9FI Alopecia areata ED70.2 Approved [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Short-chain dehydrogenase/reductase 3 (DHRS3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [35]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [36]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [37]
Panobinostat DM58WKG Chronic graft versus host disease Approved [38]
Testosterone DM7HUNW Hot flushes GA30 Approved [39]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [40]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [41]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [32]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [42]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member B15 (AKR1B15)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [21]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [43]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [44]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [45]
Arsenic DMTL2Y1 N. A. N. A. Approved [46]
Cytarabine DMZD5QR Acute lymphoblastic leukaemia 2A85 Approved [47]
Urethane DM7NSI0 N. A. N. A. Phase 4 [48]
GSK2110183 DMZHB37 leukaemia 2A60-2B33 Phase 2 [49]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [50]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aldose reductase (AKR1B1) TTFBNVI ALDR_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Aldo-keto reductase 1A1 (AKR1A1) Main DME DED2FW3 AK1A1_HUMAN Substrate [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aldo-keto reductase family 1 member B1 (AKR1B1) OTRX72TH ALDR_HUMAN Biotransformations [3]
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Regulation of Drug Effects [4]
Aldo-keto reductase family 1 member B15 (AKR1B15) OTUEXSWH AK1BF_HUMAN Regulation of Drug Effects [5]
Short-chain dehydrogenase/reductase 3 (DHRS3) OTSK1DTP DHRS3_HUMAN Regulation of Drug Effects [6]

References

1 Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20764-9.
2 The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry. 1996 Nov 12;35(45):14276-80.
3 Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. Chem Biol Interact. 2009 Mar 16;178(1-3):171-7. doi: 10.1016/j.cbi.2008.10.027. Epub 2008 Oct 25.
4 Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur J Pharmacol. 2008 Apr 28;584(2-3):213-21.
5 Functional expression of novel human and murine AKR1B genes. Chem Biol Interact. 2011 May 30;191(1-3):177-84.
6 Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). Chem Biol Interact. 2015 Jun 5;234:178-87.
7 Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
8 Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
9 Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
11 Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
12 ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
13 Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
14 A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
15 Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20.
16 Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
17 Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
18 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
19 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
20 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
21 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
22 Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
23 Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
24 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
25 Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
26 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
27 Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.
28 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
29 Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
30 Posttranslational glutathiolation of aldose reductase (AKR1B1): a possible mechanism of protein recovery from S-nitrosylation. Chem Biol Interact. 2009 Mar 16;178(1-3):250-8. doi: 10.1016/j.cbi.2008.11.007. Epub 2008 Nov 18.
31 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
32 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
33 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
34 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
35 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
36 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
37 Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
38 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
39 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
40 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
41 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
42 PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
43 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
44 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
45 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
46 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
47 Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
48 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
49 Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
50 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.